Drug Profile
Research programme: eye disorder gene therapies - Beacon Therapeutics
Alternative Names: AAV2/5-GRK1-hRPGRco; AAV2/5-GRK1-hRPGRstb; AAV2/5-GRK1-RPGR1; AAV2/5-GRK1-RPGR2; Age-related macular degeneration gene therapy- Beacon TherapeuticsLatest Information Update: 29 Jun 2023
Price :
$50
*
At a glance
- Originator Applied Genetic Technologies Corporation
- Developer Beacon Therapeutics
- Class Eye disorder therapies; Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Dry age-related macular degeneration; Stargardt disease
Most Recent Events
- 07 Jul 2022 Eye disorder gene therapies are still in preclinical development for Dry age-related macular degeneration in USA (Parenteral) (Applied Genetic Technologies Corporation pipeline, July 2022)
- 28 Nov 2021 No recent reports of development identified for preclinical development in Dry age-related macular degeneration in USA (Parenteral)
- 29 Sep 2021 Applied Genetic Technologies plans IND enabling studies for Dry age-related macular degeneration in 2022